Top Markets
#1 Black Phoenix Black Phoenix +21,279.43%
#2 Nesa Nesa +680.24%
#3 Ontology Gas Ontology Gas +79.73%
#4 Kinesis Silver Kinesis Silver +54.00%
#5 Biconomy Biconomy +38.09%
#6 QuantixAI QuantixAI +23.11%
#7 EXOD EXOD +22.78%
#8 Magma Finance Magma Finance +18.80%
#9 SAFEcoin SAFEcoin +18.27%
#10 BNB Attestation Service BNB Attestation Service +18.17%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Camurus AB Camurus AB

Camurus AB

CAMX
Rangering i aksjer #4179
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Aksjekurs
$67.97
Markedsverdi
$4.04B
Endring (1 dag)
-1.06%
Endring (1 år)
-7.50%
Land
SE
Handel Camurus AB (CAMX)

Kategori

Healthcare
Aksjeprishistorikk for Camurus AB (CAMX)
Høyeste sluttskurs: $69.18 den 2026-08-01

Laveste sluttskurs: $7.87 den 2015-12-01
Aksjeprishistorikk for Camurus AB fra 2015 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) 0.49%
2025 26.88%
2024 4.43%
2023 92.92%
2022 53.39%
2021 -24.41%
2020 143.97%
2019 -13.20%
2018 -26.98%
2017 23.80%
2016 45.06%
2015 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.93 42.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 48.01%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $147.42 496.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $766.55 6.54%
CH